C-HCCVCapsida
AAV capsid engineering, targeted genetic medicines, in-house cGMP manufacturing
deliverydeliveringgene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-HCCV
C-HCCVC-HCCVAAV capsid engineering, targeted genetic medicines, in-house cGMP manufacturing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults. Participants will have a single intravenous infusion of CAP-003 and visit the clinic regularly for 2 years for checkups and tests.
The goal of this clinical trial is to learn about the safety of CAP-002 gene therapy in children with Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy. It will also provide information about whether CAP-002 demonstrates efficacy in treating children with STXBP1 with and without seizures. Participants will have a single infusion of CAP-002, visit the clinic regularly for 2 years for checkups and tests and have seizures recorded in a diary by their caregiver.
This is a prospective, non-interventional, longitudinal study designed to characterize the natural history of STXBP1 related encephalopathy with epilepsy, in participants ≤ \<5 years of age.
BCLA's 7th Annual Biotech Summit, "How LA's Biotech Landscape is Shaping the Future", took place on Saturday, October 16, 2021 at BioscienceLA. During the keynote speech by Nick Goeden, Co-Founder and Vice President of Technology of Capsida Biotherapeutics, he addressed the challenges of starting a company during a pandemic, the spotlight the pandemic shed on the biotech industry, and the future of viral vector technology. Learn more about Capsida: https://capsida.com/ Visit our website: https://www.bc-la.org Follow us on social media: - Facebook: https://www.facebook.com/BiotechConnectionLA/ - Instagram: https://www.instagram.com/team_bcla/ - Twitter: https://www.twitter.com/Team_BCLA - LinkedIn: https://www.linkedin.com/in/bclosangeles/
Capsida Biotherapeutics is pleased to announce that AbbVie has exercised its option for the first neurodegeneration program in our ongoing partnership. This is a testament to the outstanding… | Peter Anastasiou | 23 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your c … Co. Ltd. ’ recombinant humanized monoclonal antibody MIL62 has had its new drug application accepted, likely targeting Primary Membranous Nephropathy (PMN). 🔬 About MIL62 In-house developed 3rd-gen anti-CD20 First clinical trial: Feb 2016 First clinical approval: Oct 2016 First NDA submission (neuromyelitis optica): May 2025 🏥 Phase III Progress MIL62’s Phase III trial in PMN is advancing as a multicenter, randomized, controlled, open-label study evaluating its efficacy and
Seeking Safety and Specificity in Gene Therapy, Capsida Debuts With $140 Million - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Seeking Safety and Specificity in Gene Therapy, Capsida Debuts With $140 Million April 28, 2021 | 3 min read | Heather McKenzie Twitter LinkedIn Facebook Email Print Photo courtesy of Capsida Biotherapeutics Inc. The California biotech aspires to be a catalyst for the acceleratio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Capsida and Prevail to develop CNS gene therapies Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Compani
Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities March 12, 2024 Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer Promotion reinforces commitment to advancing our wholly owned gene the
Capsida Biotherapeutics lays off staff to focus on clinical trials | Jack Shuang Hou posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig … e landscape is fragmented, capabilities vary widely, and even the most detailed RFP checklist can’t capture the nuances that define a successful partnership. In many cases, teams are left navigating a long list of potential CDMOs with limited time, resources, or experience to thoroughly assess what’s truly the right fit. What Makes CDMO Selection So Complex? Choosing the right partner goes far beyond capabilities on paper. Key factors include: 🎯 Therapy-specific requirements … 3 asset while aligning the cost with its actualized future value. The strategic prize, ixo-vec, is a one-time AAV gene therapy for wet age-related macular degeneration (wet AMD). It is engineered to enable continuous, endogenous expression of aflibercept, aiming to replace the burdensome regimen of chronic intravitreal injections. By leveraging a validated biological mechanism, the innovation risk is focused on the delivery platform's long-term safety and durability—a risk th
%PDF-1.7 %���� 1 0 obj >/Metadata 2157 0 R/ViewerPreferences 2158 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��X�n7}���nQ�;�I$h��vЇ��,�Je�+KM��=3ܫe9���/��!gxx�"r�Ϸ���l�'�^��ƣB�( �uD� �l!����'b3 M_�:����X�� � ��/��G��G��N����U��5��v��v#�7b�>��9�i!�R�8�J/��#2��u-Y�4���K�������-�5Q(������ 쁇�H��bD�7W��"����{�C6���p�yH�����D�X�삨��E��,�����+r�,��O%�K��� ���__�G�g*�C�� �^�ṳ���x�t��ś��x�L���ANQ�?]��1��lɀ&���Kbzz=۴
Rob Murphy - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities Rob Murphy Chief Manufacturing and Quality Officer Rob Murphy serves as Capsida’s Chief Manufacturing and Quality Officer. He is a seasoned biotech executive with more than 30 years of experience successfully leading operations functions through pre-clinical, clinical, and co
Capsida Biotherapeutics: Unlocking gene therapy for all | Capsida Biotherapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i
Terms of Use - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities OUR PIPELINE IS MAKING THE IMPOSSIBLE POSSIBLE TERMS AND CONDITIONS OF USE Effective date: 8/1/2025 Last updated: 4/6/2026 Welcome to Capsida. Please read on to learn the rules and restrictions that govern your use of our website (the “ Site ”). If you have any questions, c … nefit of any third party, and only in a manner that complies with all laws that apply to you. If your use of the Site is prohibited by applicable laws, then you aren’t authorized to use the Site. We can’t and won’t be responsible for your using the Site in a way that breaks the law. Usage Data In connection with your use of the Site, you may provide us (in an email or otherwise) with feedback, suggestions, improvements, enhancements, or feature requests relating to the Site ( … or usage information based on your use of the Site (“ Usage Data ”). You hereby grant Capsida a worldwide, non-exclusive, perpetual, royalty-free, fully paid, sublicensable (through multiple tiers), and transferable license to use, edit, modify, truncate, aggregate, reproduce, distribute, prepare derivative works of, display, perform, and otherwise fully exploit the Feedback and the Usage Data in connection with this Site, our services, and our (and our successors’ and assign … iolates someone else’s (including Capsida’s) rights. Subject to these Terms, we grant each user of the Site a worldwide, non-exclusive, non-sublicensable and non-transferable license to use (i.e., to download and display locally) Content solely for purposes of using the Site. Use, reproduction, modification, distribution or storage of any Content for any purpose other than using the Site is expressly prohibited without prior written permission from us. You understand that Cap … n where these functionalities exist, all the restrictions in this section still apply. Who is responsible for what I see and do on the Site? Any information or Content publicly posted or privately transmitted through the Site is the sole responsibility of the person from whom such Content originated, and you access all such information and Conten
Capsida Biotherapeutics appoints Romuald Corbau (May 2026) Following Capsida Biotherapeutics? Get the free weekly executive digest The latest leadership moves, like Capsida Biotherapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime. Weekly Digest New leadership moves, summarized for you Straight to Inbox No login, no app to check — it comes to you Leadership Trends See who's moving and how much in your market Subscribe Free No credit card required Weekly executive digest Back to Executives Capsida Biotherapeutics Appoi
Romuald Corbau, Ph.D. - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities Romuald Corbau, Ph.D. Chief Scientific Officer Romuald Corbau, Ph.D., is Chief Scientific Officer at Capsida Biotherapeutics. Dr. Corbau has over 27 years of experience in gene therapy and drug discovery across startups and global organizations in the United States
Capsida Technology and Clinical Leadership to Present at Gene Therapy for Neurological Disorders Conference - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities December 2, 2021 Capsida Technology and Clinical Leadership to Present at Gene Therapy for Neurological Disorders Conference Capsida Biotherapeutics Inc., a fully integrated biote
Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities March 7, 2023 Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer Industry veteran added to complement co-founders Nicholas Flytzanis, Ph.D. and Nick Goeden, Ph.D., to build … tigator of several National Institutes of Health (NIH) preclinical and clinical grant awards totaling more than $120 million. At the national level, she serves on the External Advisory Board for several National Institutes of Health (NIH) clinical initiatives, various NIH review panels in the areas of drug discovery and clinical development for neurodegenerative diseases, and peer-reviewed scientific journal editorial boards. Dr. Catalano is a recipient of several national re
I’m excited to share an important career transition. After an incredible journey as Co-Founder and Chief Technology Officer at Capsida Biotherapeutics, I recently transitioned to a new role as Chief… | Nick Goeden, PhD | 31 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can updat
Capsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40 - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities April 19, 2022 Capsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40 Dr. Nick Goeden and Dr. Nick Flytzanis – “the Nicks,” as many of their colleagues call them – have a lot in common. They’re both co-founde
%PDF-1.7 %���� 1 0 obj >/Metadata 1375 0 R/ViewerPreferences 1376 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��[�s�Hw���y��� e�9;�slއI��L�H$�= ��r4)G:�~�y�d1=�hJ�H)+�N"�b&`h� y8��@�$�+ ������]�X� �h�B+n���p�����#آw����,6J �+2z�*��%��`��d&$ m����㣿���n���zKd��������ů���� ;�\!�K�~+k��R�^�@�N����D�\�lU�UZĒ�u 3B����đ�� � �D�����pB#��\�*����둔Ią�J��8)X��8F-��XE͵ �>ʈ(N�5p���#¡g�X��~�p1A��r��}��$
Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities December 7, 2021 Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO Longtime industry executive Peter Anas
Nicholas Flytzanis, Ph.D. - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities Nicholas Flytzanis, Ph.D. Founder, Chief Research and Innovation Officer Nicholas Flytzanis co-founded Capsida Biotherapeutics and serves as Chief Research and Innovation Officer. Prior to co-founding Capsida, Dr. Flytzanis served as scientific director of the
Mina Kim - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities Mina Kim Interim Chief Executive Officer Mina Kim serves as Capsida’s interim Chief Executive Officer and a member of the board of directors. She has more than 20 years of operational and leadership experience. Ms. Kim previously served as Acelyrin’s Chief Executive
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Instagram Instagram Log In Sign Up Close Never miss a post from team_bcla Sign up for Instagram to stay in the loop. Sign up Log in team_bcla • Follow More options team_bcla 143w We're thrilled to introduce our newest advisory board member, Dr. Nick Goeden! His impressive background as co-founder of Capsida Biotherapeutics makes him a valuable asset to our organization. We eagerly anticipate the incredible contributions he will undoubtedly bring to our team. Welcome, Dr. Goeden! #Innovation #BCLA #Biotech Load more comments No comments yet. Start the conversation. Like Comment Share Save
#biotech #capsida #losangelesjobs | Nick Goeden, PhD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy ,
%PDF-1.7 %���� 1 0 obj >/Metadata 1135 0 R/ViewerPreferences 1136 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��X�n�H}��G2�Z}g0 زc�%O�Y`��LK�Ȓ�d6���9U�e)�b � ����d�~�ÅP����b r�u~�! �ϥ��6��r4�֤e����1�Ƣ��d� 碄3�eRE��1�BѭSԺ�-���y��51 ���Ƣ�\,�")�����סx>{��v�p^d�Bk/�r�� ���� � �� ���� ��HC�fX�9� �26*��Ӂ;��m���f�oy���e+Ck���� ���%��Jկ\Ϊi��jRI4����H� �Qk�SEj!L�Nz�;@q$�H� ��촇쥗V��7G\�D�s�� ���љ,iL�T���GC&E�t2F�uҔk0���Z� �D
Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy — STXBP1 Foundation 0 Skip to Content What is STXBP1? Patients & Families Genetic Testing Newly Diagnosed Register in our Contact List Enroll in STARR Study Clinical Trials and Research World Map Clinicians Family Resources Clinics Global Connect Partners in Advocacy The Scientific Director's Corner Glossary VIP Siblings Kits Researchers Researcher Resources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride G … ources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & References News & Events News Blog Newsletter Podcasts Events Summit+ 2026 Researcher Roundtable 2026 September Awareness Month Move To Cure Million Dollar Bike Ride Past Conferences Patient-Focused Drug Development Meeting Get Involved Fundraise Ways to Give Volunteer … ources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & References Folder: News & Events Back News Blog Newsletter Podcasts Events Summit+ 2026 Researcher Roundtable 2026 September Awareness Month Move To Cure Million Dollar Bike Ride Past Conferences Patient-Focused Drug Development Meeting Folder: Get Involved Back Fundrai
Systemic AAV Gene Therapy with Next Generation Engineered Capsids for Treatment of CNS and Cardiac Symptoms in Friedreich’s Ataxia - MDA Clinical & Scientific Conference 2026 and tags on every page of your site. --> Register Now --> Home MDA Conference 2026 Registration Rates Agenda Location & Venue Our Sponsors CE Media Information Sponsorships & Exhibits Sponsorship Levels Event Sponsorships Marketing Sponsorships Exhibit Information Patient Advocacy Pavilion Abstracts 2026 Abstract Guidelines 2026 Abstract Library 2025 Abstract Library 2024 Abstract Library 2023 Abstract Libra … Demand Conference About Us About The MDA Conference About MDA Awards MDA Legacy Award for Achievement in Clinical Research The MDA Donavon Decker Community Impact in Research Award MDA Research Momentum Award Future Conferences Contact Us Home MDA Conference 2026 Registration Rates Agenda Location & Venue Our Sponsors CE Media Information Sponsorships & Exhibits Sponsorship Levels Event Sponsorships Marketing Sponsorships Exhibit Information Patient Advocacy Pavilio … Demand Conference About Us About The MDA Conference About MDA Awards MDA Legacy Award for Achievement in Clinical Research The MDA Donavon Decker Community Impact in Research Award MDA Research Momentum Award Future Conferences Contact Us Systemic AAV Gene Therapy with Next Generation Engineered Capsids for Treatment of CNS and Cardiac Symptoms in Friedreich’s Ataxia Topic: Translational Research Poster Number: O258 Author(s): Ryan Kast, PhD, Capsida Biotherapeutics, Celeste
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Media Library | ASGCT Javascript must be enabled for the correct page display 100"> Skip to main ASGCT.org Annual Meeting Patient Education Molecular Therapy Journals { if (window.innerWidth > this.breakpoint) { this.dropdownOpen.lg = index; } }, 100); }, handleMouseLeave() { clearTimeout(this.timeout); this.timeout = setTimeout(() => { if (window.innerWidth > this.breakpoint) { this.dropdownOpen.lg = null; } }, 100); } }"> Sign In Join Partner with ASGCT Pressroom Search this site Search all ASGCT.org sites Search this site Search all ASGCT.org sites $refs.input.value = value)"> Keywords 0" x … etter breakpoint) childOpen.lg = 6" class="py-2 lg:px-6" > Congressional Policy Fellowship breakpoint) { dropdownOpen.lg = 4; align = menuSides[4] || 'left'; }" role="presentation" class="relative lg:border-0 border-b border-gray-200" @mouseenter="handleMouseEnter(4)" @mouseleave="handleMouseLeave()" > News + Publications News + Publications { this.childOpen.lg = null; }); const mainMenuEl = this.$el.closest('#main-menu'); if (mainMenuEl) { const mainComponent = Alpine.$data( … ns const maxHeight = Math.max(...visibleDropdowns.map(d => d.scrollHeight)); // Apply the same max height to ALL visible dropdowns visibleDropdowns.forEach(dropdown => { dropdown.style.height = `${maxHeight}px`; }); }, calculateMenuPositions() { if (window.innerWidth > this.breakpoint) { const topbar = this.$refs.topbar; if (!topbar) return; const topbarRect = topbar.getBoundingClientRect(); const topbarCenter = topbarRect.left + topbarRect.width / 2; // Store whether each me … 0 lg:pt-2 lg:px-6 mr-4 lg:mr-0 lg:no-underline lg:pb-0 " > Congressional Policy Fellowship this.breakpoint) { dropdownOpen.lg = 4; align = menuSides[4] || 'left'; $el.setAttribute('data-align', align); }" role="presentation" class="relative lg:border-0 pb-5 lg:pb-0 " @mouseenter="handleMouseEnter(4)" @mouseleave="handleMouseLeave()" > News + Publications News + Publications { if (window.innerWidth > this.breakpoint) { this.childOpen.lg = index; this.$el.closest('#main-menu'). … Formats Videos Podcasts Year All Years 2026 2025 2024 2023 2022 2021 2020 2019 Apply Filters Clear All Filters i !== 0) : expanded.push(0) " tabindex="0" class="text-left leading-6 w-full bg-primary text-white font-normal accordion-title gap-x-4 flex justify-between items-center py-4 relative px-4 md:px-8 font-display text-22 lg:text-30 leading-
Capsida, Adverum, Instil and Metagenomi Showcase Therapies at ASGCT (Updated) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Capsida, Adverum, Instil and Metagenomi Showcase Therapies at ASGCT (Updated) May 18, 2022 | 4 min read | Alex Keown Twitter LinkedIn Facebook Email Print The American Society of Gene and Cell Therapy annual meeting continues to see companies showcasing promising therapeu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Capsida’s gene therapy for STXBP1 developmental and epileptic encephalopathy gains IND clearance | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's
Child dies in Phase I Capsida gene therapy trial - Clinical Trials Arena Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Pro
Capsida’s investigational epilepsy gene therapy gets orphan status | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 land
Gene therapy startup Capsida banks $140M in series A round plus Abbvie deal | 2021-04-29 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health
Instagram Instagram Log In Sign Up Close Never miss a post from geneonlineus Sign up for Instagram to stay in the loop. Sign up Log in geneonlineus • Follow More options geneonlineus 57w ASGCT 2025 Abstract [93] 🧬 Capsida Biotherapeutics has identified five novel blood-brain barrier (BBB) receptors using its high-throughput AAV capsid engineering platform. 🧠 Key scientific insights: 🔸 These newly discovered receptors exhibit superior specificity to brain vasculature and enable highly selective transport of gene therapy payloads across the BBB. 🔸 Engineered AAV capsids using these receptors
BoBJPM Peter Anastasiou Capsida Biotherapeutics Get more Bioprocess insight with our FREE newsletter sign me up Log In or Subscribe Explore Bioproduction Cell Line Development Upstream Bioprocessing Downstream Bioprocessing Formulation Fill/Finish Cold Chain Management Quality Control & Assurance Find Suppliers Cell Culture Media Fermentation Filtration Fluid Management Purification Watch Now STREAM Video Channel Better Biopharma Podcast Bioprocess Online Live Bio-Expo Live The Business Of Biotech Podcast Our Communities Advancing RNA Biosimilar Development Cell & Gene Clinical Supply … specific interests: Job Title Company What topics interest you? (Check all that apply.) Downstream Manufacturing Facilities Design Fill-Finish Manufacturing Controls Outsourcing Process Engineering Quality & Analytical Methods Regulatory Supply Chain Upstream Manufacturing Save and Access Content Newsletter Signup I agree to the Terms . I consent to the processing of my personal data for follow-up and B2B marketing communications by Life Science Connect and our trusted sp
Capsida Biotherapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities December 19, 2024 Capsida Biotherapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference THOUSAND OAKS, Calif., December 19, 2024 — Capsida Biotherapeutics (“Capsida”), leader in next-genera
Register to Exhibit at the Largest & Original Forum for Prec. Med Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdo … ogin / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry media / influencer pass CONTACT US ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ GET UPDATES Past Event PMWC, Feb 5-7, 2025 Attend Program Schedule Honorees Speakers Showcases Exhibits + Map Travel Venue Sightseeing Reduced Rates Hotel Flights Login / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to sp … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities January 4, 2023 Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly,
Virtual Press Office: Trade show news, exhibitor news, online press kits --> Send a News Release --> Blog For Journalists News Solutions Resources --> --> Overview Marketing Public Relations IR & Compliance Agency All Products Contact Us Journalists Blog Become a Member Send a Release --> Order a Press Kit News Solutions Resources --> Search Contact Us +1 973-783-7787 option 0 Home Products Event Organizer Services News Releases Events Press Services Overview Marketing Public Relations IR & Compliance Agency All Products --> News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29
Instagram Instagram Log In Sign Up Close Never miss a post from stxbp1_foundation Sign up for Instagram to stay in the loop. Sign up Log in stxbp1_foundation • Follow More options stxbp1_foundation 2w ✨A Message from the STXBP1 Foundation Board President: “With the close of the Capsida clinical trial, many families have asked me and other board members: What do we do now; how do we move forward? As parents, we know there was so much hope attached to that first gene therapy clinical trial for STXBP1. I want to assure you that there is reason to still have HOPE. The Capsida gene therapy was only
#genetherapy #asgct2023 | Capsida Biotherapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , an
Instagram Instagram Log In Sign Up Close Never miss a post from biotechtvhq Sign up for Instagram to stay in the loop. Sign up Log in biotechtvhq Verified • Follow More options biotechtvhq Verified 58w 𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟓: Capsida Biotherapeutics is using its expertise in capsid design to develop gene therapies that are tissue specific, and in the case of the CNS, can be delivered via IV and crosses the BBB. #ASGCT2025 Load more comments No comments yet. Start the conversation. Like 2 Comment Share Save May 14, 2025 Log in to like or comment. More posts from biotechtvhq Clip Clip Clip Clip Cli
Capsida Biotherapeutics Announces Publication in Nature Neuroscience From Caltech Demonstrating Robust, Non-invasive IV Gene Delivery Targeted to the Brain While Avoiding Liver | Denny Muha LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings
Capsida Biotherapeutics Names Susan Catalano Chief Scientific Officer | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscribe
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy — STXBP1 Foundation 0 Skip to Content What is STXBP1? Patients & Families Genetic Testing Newly Diagnosed Register in our Contact List Enroll in STARR Study Clinical Trials and Research World Map Clinicians Family Resources Clinics Global Connect Partners in Advocacy The Scientific Director's Corner Glossary VIP Siblings Kits Researchers Researcher Resources Basic and Preclinical Research Clinical Trials … ources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & References News & Events News Blog Newsletter Podcasts Events Summit+ 2026 Researcher Roundtable 2026 September Awareness Month Move To Cure Million Dollar Bike Ride Past Conferences Patient-Focused Drug Development Meeting Get Involved Fundraise Ways to Give Volunteer … ources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & References News & Events News Blog Newsletter Podcasts Events Summit+ 2026 Researcher Roundtable 2026 September Awareness Month Move To Cure Million Dollar Bike Ride Past Conferences Patient-Focused Drug Development Meeting Get Involved Fundraise Ways to Give Volunteer … ources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & References Folder: News & Events Back News Blog Newsletter Podcasts Events Summit+ 2026 Researcher Roundtable 2026 September Awareness Month Move To Cure Million Dollar Bike Ride Past Conferences Patient-Focused Drug Development Meeting Folder: Get Involved Back Fundrai … BP1-DEE). These data were the foundation for the Investigational New Drug (IND) application for CAP-002 that was recently cleared by the U.S. Food and Drug Administration (FDA). Capsida will deliver these data in an oral presentation today at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 13-1
Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene & Cell Therapy 26th Annual Meeting Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News R … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Industry Sponsored Symposium - Capsida Biotherapeutics | ASGCT Javascript must be enabled for the correct page display 100"> Skip to main ASGCT.org Annual Meeting Patient Education Molecular Therapy Journals { if (window.innerWidth > this.breakpoint) { this.dropdownOpen.lg = index; } }, 100); }, handleMouseLeave() { clearTimeout(this.timeout); this.timeout = setTimeout(() => { if (window.innerWidth > this.breakpoint) { this.dropdownOpen.lg = null; } }, 100); } }"> Sign In Join Partner with ASGCT Pressroom Search this site Search all ASGCT.org sites Search this site Search all ASGCT.org sites $ … etter breakpoint) childOpen.lg = 6" class="py-2 lg:px-6" > Congressional Policy Fellowship breakpoint) { dropdownOpen.lg = 4; align = menuSides[4] || 'left'; }" role="presentation" class="relative lg:border-0 border-b border-gray-200" @mouseenter="handleMouseEnter(4)" @mouseleave="handleMouseLeave()" > News + Publications News + Publications { this.childOpen.lg = null; }); const mainMenuEl = this.$el.closest('#main-menu'); if (mainMenuEl) { const mainComponent = Alpine.$data( … ns const maxHeight = Math.max(...visibleDropdowns.map(d => d.scrollHeight)); // Apply the same max height to ALL visible dropdowns visibleDropdowns.forEach(dropdown => { dropdown.style.height = `${maxHeight}px`; }); }, calculateMenuPositions() { if (window.innerWidth > this.breakpoint) { const topbar = this.$refs.topbar; if (!topbar) return; const topbarRect = topbar.getBoundingClientRect(); const topbarCenter = topbarRect.left + topbarRect.width / 2; // Store whether each me … 0 lg:pt-2 lg:px-6 mr-4 lg:mr-0 lg:no-underline lg:pb-0 " > Congressional Policy Fellowship this.breakpoint) { dropdownOpen.lg = 4; align = menuSides[4] || 'left'; $el.setAttribute('data-align', align); }" role="presentation" class="relative lg:border-0 pb-5 lg:pb-0 " @mouseenter="handleMouseEnter(4)" @mouseleave="handleMouseLeave()" > News + Publications News + Publications { if (window.innerWidth > this.breakpoint) { this.childOpen.lg = index; this.$el.closest('#main-menu').
Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene & Cell Therapy 26th Annual Meeting - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities May 10, 2023 Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene &
%PDF-1.7 %���� 1 0 obj >/Metadata 2202 0 R/ViewerPreferences 2203 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��TKk�@� � �(���B �ӐЀ[;�PzFv�8��J�}gV��&J!�2�������~U.�pvs�҄g�s!%w,�94U�|;�:M�˹��2�r����OP� > endobj 6 0 obj > stream x�c��bE� �?u��(Ed!��C�磁/:;ECQ� endstream endobj 7 0 obj >>> endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > stream x�읅����3�Iv��(- … &�4��V�(�NGL������q�\O�n���;��Oa+�Wb�� )�Q��r�ʹ��U�{(c��ol�Y�1��v�=Rfp���c�����n�b����`� ) ON��Q�Q�i��M�W�T�z���ʵ �����t8pg�������Y,�����xkö����"�o4S�#����A���1�z����ʕ�mʑ�k��|3ev�jR\N� ��F�����������b9�hn�I��z�;��S�n�t� �:�bP4эʹ%�p+F��x }� dd��d2=@�Xz�PZ�-��*�[,��В>S���E1>ʲ(��nPGQ����Z�im����e܃vFWӷ#�A��L�B��yel���=kKC1��k�,��B�y,���:�ϥuP�Fs�֕��X� ��e�1���+V�l�^�ڐΚŖ9�bCp�iڝ�W�u-��� ����y�N� �tP/� Q ����ֲ��e��ץ@�*e���M �� �Xn$�K A
Connect with Capsida at ASGCT - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities Connect with Capsida at ASGCT Connect with Capsida at ASGCT May 16-20, 2023 Los Angeles, California Are you attending the American Society of Gene and Cell Therapy Annual Meeting in LA? If so, we’d love to connect with you. Please come by and say hi, and ma
%PDF-1.7 %���� 1 0 obj >/Metadata 2777 0 R/ViewerPreferences 2778 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��XMo7� ��q7���7�I�h�v�Cу"˲RY��RS����e9�����ΐ3 �y3"w��v����w���k��xT�BE��.�(}!�-�v1 ��Blƣ�3'����vr�Ua�`�����H����5���>���l�[l7b~+��A�ΡL ���IUzq= �q-�k�J�����U_!�GbC$�4�+aKiM ����Ho��CZ$�PX1GD��׳�"�7�xx�C48LeM�����sx�^�(���%Aϋ�RyY�g�0ίɕ�p�>��.9gJs��~7 ����wq��x���C&=��������߈��+q�r���t�RǔKdKhr�� \ӳ�٦�IM�
%PDF-1.7 %���� 1 0 obj >/Metadata 1851 0 R/ViewerPreferences 1852 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��X�r��}g�a �-q�������͊7�Wk)�VRy@H����|���AR$W)�~�؍��ӧ{��6�jR�����\���KD"�$QZ'���D8�����>� �~oxu��t��)1�'�J��Z=��������ux���V�}>n��lj1Z��M&#(�#�R�8��T �G���`&r�z�f�d�ß�� -Z� `�J�8L��?m����:;��$��A!��2Wl�v�RV�n�b+��}�22�l����R?k)^�� ��@��Q�8"ɚ�j@��WQ ���jm��2��oCt�$��7��Ba�p�w;n}o�e�W�jT,�y-��q����e�8+
Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich's Ataxia Next-Generation Gene Therapy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich’s Ataxia Next-Generation Gene Therapy November 13, 2024 | 4 min read Twitter LinkedIn Facebook Email Print NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and sensory manifestations of Friedrei … s, especially the liver. CAP-004 is now entering Investigational New Drug (IND) application enabling studies. Data highlighting the therapeutic potential of CAP-004 will be presented in a late-breaking poster presentation at the International Congress for Ataxia Research (ICAR), being held November 12-15, 2024 in London, UK . Friedreich's ataxia is a rare hereditary disease with limited treatment options. It is caused by a mutation that reduces frataxin (FXN) protein expressi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Devel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy May 29, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Capsida previously received FDA Orphan Drug Designation and IND clearance to initi … may be eligible for more frequent meetings and communications with the FDA and rolling review of application for marketing approval. A Fast Track-designated drug also may be eligible for Priority Review if relevant criteria are met. “FDA’s granting of Fast Track designation for CAP-002 highlights the significant unmet need in the treatment of STXBP1-DEE and the potential of CAP-002 to be a first-in-class treatment,” said Swati Tole, M.D., Chief Medical Officer of Capsida Bio … sp; 3 min read · Heather McKenzie Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Policy HHS debuts ‘unprecedented’ initiative to ‘restore American leadership’ in clinical trials June 22, 2026 · 3 min read · Heather McKenzie FDA REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recen … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities October 3, 2023 Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies Strat
Capsida | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Capsida Website: Capsida Business Area(s) Cell and Gene Therapy AAV Central Nervous System RNA Description Capsida is a biotechnology company that is developing a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CN
Error Facebook Facebook is not available on this browser To continue using Facebook, get one of the browsers below. Learn more English (US) + Meta © 2026
STAT - Some in the gene therapy field lament lost time... Facebook Log In STAT's Post STAT Verified account May 12 · Shared with Public Some in the gene therapy field lament lost time while Capsida kept silent about the brain receptor it was targeting when things went wrong. statnews.com Capsida says it still doesn’t know what caused gene therapy death Like Comment
Instagram Instagram Log In Sign Up Close Never miss a post from stxbp1_foundation Sign up for Instagram to stay in the loop. Sign up Log in stxbp1_foundation • Follow More options stxbp1_foundation 58w 📣Capsida Biotherapeutics has announced that it received approval from the FDA for its Investigational New Drug (IND) Application for its gene therapy CAP-002, developed for STXBP1-RD. CAP-002 uses Capsida’s engineered AAV capsid that crosses the blood–brain barrier while detargeting the liver and sensory nerves, enabling widespread neuronal delivery after an IV infusion. This is more than indus
CAP-002 / Capsida Biotherap CAP-002 / Capsida Biotherap - LARVOL DELTA Home Next Prev 1 to 12 Of 12 Go to page 1 June 11, 2026 A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy (clinicaltrials.gov) - P1/2 | N=1 | Terminated | Sponsor: Capsida Biotherapeutics, Inc. | N=12 ➔ 1 | Trial completion date: Dec 2028 ➔ May 2026 | Suspended ➔ Terminated | Trial primary completion date: Dec 2028 ➔ Mar 2026; Stopping rule for study was met Enrollment change • Trial completion date • Trial primary completion date • Trial termination • CNS … od and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-002, its wholly owned first-in-class, intravenously (IV) administered gene therapy to enter clinical trials for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). This is the first program entering a human clinical trial utilizing an IV-administered, blood brain barrier-crossing engineered capsid that also is detargeted from off-target tissues,
systemic gene therapy with engineered aav demonstrates preclinical efficacy and safety supporting a disease-modifying treatment for stxbp1 developmental and epileptic encephalopathy Career Center AES Connect Donate supervisor_account check_circle Get Involved search search Search menu Menu Home Abstracts Abstracts Systemic Gene Therapy with Engineered AAV Demonstrates Preclinical Efficacy and Safety Supporting a Disease-Modifying Treatment for STXBP1 Developmental and Epileptic Encephalopathy Abstract number : 1.237 Submission category : 2. Translational Research / 2D. Models Year : 2024 Submi … ucation arrow_drop_down AES Learn Resident Courses Epilepsy and Neurophysiology Fellowship Match Membership arrow_drop_down Become a Member Get Involved In Memoriam Directory (Members Only) Give arrow_drop_down Make a Gift Planned Giving Your Dollars at Work Targeted Funds Corporate Support About arrow_drop_down About AES Publications & Reports Press Room Reach Members Epilepsy Leadership Council Contact AES arrow_upward Back to top Terms of Use Disclosure P
%PDF-1.7 %���� 1 0 obj >/Metadata 2125 0 R/ViewerPreferences 2126 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��TMo�0 ���Q.P���lE���+�-)vv� '��8�c`ؿ ������u�z��d��E�>������%� �����r��X�� ��'P�A �[D����+k�)^>�dI��)0�4ha���^��r��Tf�p-e�=���f=�~���E�E&5���db�^�\��� ]3���ej�ѕ9 }���@� }����+,o��j��_��2wc� I�:���������u�_�{��t"V�q,N�{���|`����Xæ`�ā�l���R�h��f⢓ޙ���I�_s�AY9:&�H�eo�eY��V5)ud� r�1wh > endobj 6 0 obj
Capsida Biotherapeutics Jobs | BioBae Bio Bae Browse Jobs Companies For Employers Home / Companies / Capsida Biotherapeutics C Capsida Biotherapeutics Biotechnology 📍 Thousand Oaks , CA Capsida Biotherapeutics is a clinical-stage gene therapy company using AAV technology to develop targeted, non-invasive treatments for rare diseases. Visit website → View careers page → Open Positions at Capsida Biotherapeutics 0 positions available No open positions at the moment Check back later for new opportunities! Bio Bae The premier job board for biotech, pharma, and life sciences professionals. For Job
Episode 6: Peter Anastasiou, CEO of Capsida Biotherapeutics - Biocom Skip to main content Search Cancel Select Location Choose a location San Diego Greater Los Angeles Bay Area Seattle Sacramento Washington, D.C. Tokyo Enter your location ZIP Code Submit Location Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podcast Episodes About About Us Our Team Board of Directors Car … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Membership Member Benefits Become a Member Conference & Events Funding & Partnering Group Purchasing Policy & Advocacy Workforce Development International Connections Increase Visibility Community Building Catalyst: Innovators Under 40 CEO/Founder Network Converge … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podc
%PDF-1.7 %���� 1 0 obj >/Metadata 2393 0 R/ViewerPreferences 2394 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��X�n7}���nQ�;�I$h��vЇ��,�Je�+KM��=3ܫe9���/��!gxx�"r�?lw���|'N�G�(dQJ�"����Bl�ѯ��f �I�������˷�D��8yՃ���p� B�c�%ْM ���:7!�ɍ�V�vNo ��U�e�Î[���O�?��a�m��rhZ}��)�&��3�ۗK�i��:�9y�?v|��`�ˡ[%��'�}���VW������u��D�߮M���x���Y �O֣�[�?��S8�A�4��@ڶ����&-�pvI}�,�N t`��y��V'7��i���t�9�,v�]��Q6��t����˽^K��ۦ���
Capsida Careers | Levels.fyi Download App Change Login Sign Up All Data By Location By Company By Title Salary Calculator Chart Visualizations Verified Salaries Internships H-1B Salaries Negotiation Support Compare Benefits Who's Hiring 2025 Pay Report Top Paying Companies Integrate Blog Press Google Software Engineer Product Manager New York City Area Data Scientist Explore By Different Titles Levels FYI Logo Salaries 📂 All Data 🌎 By Location 🏢 By Company 🖋 By Title 🏭️ By Industry 📍 Salary Heatmap 📈 Chart Visualizations 🔥 Real-time Percentiles 🎓 Internships 🛂 H-1B Salaries ❣️ C … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Featured Jobs No featured jobs found for Capsida Related Companies Roblox Facebook Databricks Dropbox Lyft See all companies ➜ Other Resources End of Year Pay Report Calculate Total Comp Featured Jobs No featured jobs found for Capsida Related Companies Roblox Facebook Databricks Dropbox Lyft See all companies ➜ Other Resources End of Year Pay Report Calculate Total Comp Request an AI summa
Capsida Biotherapeutics | Biotechnology | The Pharmaletter Thursday 25 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes … with Lilly 24 June 2026 Biotechnology Ollin Bio lands $330 million Series B to fund late-stage retinal disease studies 24 June 2026 Biotechnology 105M upfront for Antares in Novartis deal 24 June 2026 Biotechnology EC backs Padcev-Keytruda combination before and after surgery in bladder cancer 24 June 2026 Biotechnology Combotope Thera enters collaboration with Boehringer 24 June 2026 Biotechnology Osanni Bio raises $190 million Series B to advance therapeutics platform 24 J
Tragedy in Pioneering Gene Therapy Trial: Capsida Halts Study After First Patient’s Death – Patient Worthy About Meet Our Contributors Meet Our Partners Meet the Patient Worthy Team Collaborative Content On Patient Worthy Diseases Share Your Story Patient Worthy Content Submission Guidelines Patient Worthy Writing Prompts Submit Your Story Patient Stories Resources Library Events Patient Worthy FAQs Podcast Contact Menu About Meet Our Contributors Meet Our Partners Meet the Patient Worthy Team Collaborative Content On Patient Worthy Diseases Share Your Story Patient Worthy Content Submis … ory Patient Worthy Content Submission Guidelines Patient Worthy Writing Prompts Submit Your Story Patient Stories Resources Library Events Patient Worthy FAQs Podcast Contact Search for: Join PW Click Here To Share Your Story With Myelofibrosis With Anemia Click Here to Read Real Patient & Caregiver Stories Click Here To Share Your Story With MASH Tragedy in Pioneering Gene Therapy Trial: Capsida Halts Study After First Patient’s Death Home > 2025 > September > 15 > Rare … by telling us a little bit about yourself! Let’s Work Together! Partner With Us Submit a Story Keep Up to Date Subscribe to Our Newsletter Check Out Rare Events Get Inspired By Our Memes Learn More About Us Rare Diseases and Conditions Terms of Use Privacy Notice Privacy Policy for CA Residents EU/UK Privacy Notice Data Privacy Framework: Consumer Privacy Policy Consumer Health Data Privacy Policy Cookie Notice Facebook-f Twitter Instagram Podcast Youtube Tiktok Linkedin-in P … re Here! What best describes you when it comes to rare disease? (check all that apply) Patient Parent Caregiver Friend Advocate Healthcare Provider Other What rare disease(s)/conditions are most important to you? --> Visit Home Page or × --> Thank you for signing up for a Patient Worthy Account! Have a rare disease story to share? Let us know Share Story Sign Up For Our Newsletter I Agree to Terms of Use & Privacy Policy --> - OR - Sign Up For Our Patient Panel Make a d
%PDF-1.7 %���� 1 0 obj >/Metadata 2392 0 R/ViewerPreferences 2393 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��XKo7� ���nQ�7 �$ 4@Z;��A�eY��u�R���� �iIN+'�e�3��|�ג;��ڮ�f�-�� �G�( �T�!��)�Z�G�>��x4}snay7 IX�� ' m����G?�G��N��P�Hs�Ƈ�v��60���wsd&C$%A[!����kj]SF�DM"-��=� �D���`�0:�DҚ %TK��T ���_ތG�e2� .ލG�/:Ϥ�� }���+(^���W=�)ꏧ� �*�X" �dO�Wr �緳M�IN�m��-6����C�_� fEߩFJ� hiE ɩ�*�� � r� _��e3z���gw��يF�4� ȍ�Έ�%Mli
Capsida Biotherapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Capsida Biotherapeutics NEWS JOBS IN THE PRESS AWARDS Gene therapy Capsida Reports Patient Death in Gene Therapy Trial Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of epilepsy. September 11, 2025 · 2 min read · Tristan Manalac Dru … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities May 12, 2025 Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encep … od and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-002, its wholly owned first-in-class, intravenously (IV) administered gene therapy to enter clinical trials for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). This is the first program entering a human clinical trial utilizing an IV-administered, blood brain barrier-crossing engineered capsid that also is detargeted from off-target tissues,
STXBP1 Foundation President and Executive Director Comment on Capsida's FDA Approval to Start Gene Therapy Clinical Trial — STXBP1 Foundation 0 Skip to Content What is STXBP1? Patients & Families Genetic Testing Newly Diagnosed Register in our Contact List Enroll in STARR Study Clinical Trials and Research World Map Clinicians Family Resources Clinics Global Connect Partners in Advocacy The Scientific Director's Corner Glossary VIP Siblings Kits Researchers Researcher Resources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Doll … ources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & References News & Events News Blog Newsletter Podcasts Events Summit+ 2026 Researcher Roundtable 2026 September Awareness Month Move To Cure Million Dollar Bike Ride Past Conferences Patient-Focused Drug Development Meeting Get Involved Fundraise Ways to Give Volunteer … ources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & References Folder: News & Events Back News Blog Newsletter Podcasts Events Summit+ 2026 Researcher Roundtable 2026 September Awareness Month Move To Cure Million Dollar Bike Ride Past Conferences Patient-Focused Drug Development Meeting Folder: Get Involved Back Fundrai … d that it received approval from the FDA for its Investigational New Drug (IND) Application for its gene therapy CAP-002, developed for STXBP1-RD. CAP-002 uses Capsida’s engineered AAV capsid that crosses the blood–brain barrier while detargeting the liver and sensory nerves, enabling widespread neuronal delivery after an IV infusion . This is more than industry news -- it's a fresh dose of hope for every family living with STXBP1, and an affirmation that STXBP1 research is m
Capsida Biotherapeutics | Portfolio | Versant Ventures Home Discovery Engines Team Portfolio Offices News ← View Portfolio Capsida is creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders. Company Name Capsida Biotherapeutics Company Website https://capsida.com/ Location San Diego, CA Connected News CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia Capsida Biotherapeutics Debuts with $140 Million of Capital LP Access Ne
Capsida Clinical Trial Information — STXBP1 Foundation 0 Skip to Content What is STXBP1? Patients & Families Genetic Testing Newly Diagnosed Register in our Contact List Enroll in STARR Study Clinical Trials and Research World Map Clinicians Family Resources Clinics Global Connect Partners in Advocacy The Scientific Director's Corner Glossary VIP Siblings Kits Researchers Researcher Resources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & … ources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & References News & Events News Blog Newsletter Podcasts Events Summit+ 2026 Researcher Roundtable 2026 September Awareness Month Move To Cure Million Dollar Bike Ride Past Conferences Patient-Focused Drug Development Meeting Get Involved Fundraise Ways to Give Volunteer … ources Basic and Preclinical Research Clinical Trials and Observational Studies Apply for a Grant Million Dollar Bike Ride Grants for STXBP1 Research Funding Recipients S-COMB Consortium Publications & References Folder: News & Events Back News Blog Newsletter Podcasts Events Summit+ 2026 Researcher Roundtable 2026 September Awareness Month Move To Cure Million Dollar Bike Ride Past Conferences Patient-Focused Drug Development Meeting Folder: Get Involved Back Fundrai
10-K 0001674416 FY 00-0000000 false P2Y no no --12-31 0001674416 crsp:TwoThousandTwentyOneAtMarketOfferingMember crsp:SalesAgreementWithJefferiesLLCMember 2022-01-01 2022-12-31 0001674416 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001674416 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001674416 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001674416 crsp:TwoThousandAndNineteenLeaseMember 2019-05-31 0001674416 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnte … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth compan … tions in clinical trials, non-clinical experiments and Investigational New Drug application-enabling studies ; • the actual or potential benefits of FDA designations, such as orphan drug, fast track and regenerative medicine advanced therapy, or such European equivalents, including the PRIority MEdicines, or PRIME, designation, as well as anticipated regulatory filings for exa-cel and the timing of such regulatory submissions to the FDA; • our ability to advance … the process of precisely altering specific sequences of genomic DNA. We aim to apply this technology to disrupt, delete, correct and insert genes to treat genetically defined diseases and to engineer advanced cellular therapies. We believe that our scientific expertise, together with our gene editing approach, may enable an entirely new class of highly effective and potentially curative therapies for patients with both rare and common diseases for whom current biopharmaceuti … ennifer Doudna of the University of California, Berkeley, shared the 2020 Nobel Prize in Chemistry for their groundbreaking work. We have acquired rights to the intellectual property encompassing CRISPR/Cas9 and related technologies from Dr. Charpentier and continue to strengthen our intellectual property estate through our own research and addit
Capsida's AAV platform nets $40M AbbVie milestone payment Drug Discovery and Development Home Drug Discovery and Development Drug Discovery Women in Pharma and Biotech Oncology Neurological Disease Infectious Disease Resources Video features Podcast Views Webinars Pharma 50 2026 Pharma 50 2025 Pharma 50 2024 Pharma 50 2023 Pharma 50 2022 Pharma 50 2021 Pharma 50 Advertise SUBSCRIBE How Capsida’s unconventional funding strategy and capsid technology promise to reshape CNS treatments By Brian Buntz | February 1, 2025 Capsida Biotherapeutics, a gene therapy startup that has quietly amassed a
CRISPR Therapeutics and Capsida Biotherapeutics… | CRISPR Therapeutics Menu ABOUT US Who We Are Gene Editing Leadership Corporate Responsibility Partnerships News Contact Therapies Pipeline FOCUS AREAS Hemoglobinopathies Immuno-Oncology Autoimmune In Vivo Regenerative Medicine CRISPR-X PATIENTS Patient Advocacy Community Voices Current Clinical Research Expanded Access to Investigational Medicines Careers Investors Press Release CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s At
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities June 15, 2021 CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edit
Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities January 18, 2023 Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer Hakim brings more than 25 years’ experience leading finance and exponential growth at both lar
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Over … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Capsida Biotherapeutics Debuts with $140 Million of Capital Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Ov … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
PharmaVoice profiles Capsida CEO Peter Anastasiou - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities February 3, 2022 PharmaVoice profiles Capsida CEO Peter Anastasiou Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality Anastasiou’s key to leadership stands at the intersection of what’s right for patients a
Capsida Biotherapeutics Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo Capsida Biotherapeutics Capsida Biotherapeutics Thousand Oaks, CA Watchlist Export About Financials People Deals Funding About Capsida Biotherapeutics Company overview Capsida Biotherapeutics is a privately-held biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases. Capsida Biotherapeutics was founded in 2019 by Nicholas Flytzanis, Nick Goeden, and Viviana
Press Releases - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities PRESS RELEASES CATCH UP WITH OUR LATEST PRESS RELEASES May 12, 2026 Capsida to Present Preclinical Data of New Next-Generation, High-Performing Ocular Capsids at ASGCT Annual Meeting June 11, 2025 Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for
%PDF-1.7 %���� 1 0 obj >/Metadata 2303 0 R/ViewerPreferences 2304 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��U[k�P ~7�?��.���/P Mӕ��%ec&8I�����ؿ�t�%�� ھ(�t$}:��R�7ۻU���xz?҄g�s!%w,�94U�|9�:M����� *�r����/P� �,�]0��+�W��$M>� \b(��e �����z��X�kȪzt;���` c�rW�o��I��E��״X�C]*΄�]b*�0 s6� \B� 4��#h��re�9�]�V��wZt,�fgkH�$���P�1UL�t�>;�Z��?�̓x� �D���a 1�q�Y��/qy0B��q�j ����G7��FQ��#U�F �����] > endobj 6 0 obj > stream … &�4��V�(�NGL������q�\O�n���;��Oa+�Wb�� )�Q��r�ʹ��U�{(c��ol�Y�1��v�=Rfp���c�����n�b����`� ) ON��Q�Q�i��M�W�T�z���ʵ �����t8pg�������Y,�����xkö����"�o4S�#����A���1�z����ʕ�mʑ�k��|3ev�jR\N� ��F�����������b9�hn�I��z�;��S�n�t� �:�bP4эʹ%�p+F��x }� dd��d2=@�Xz�PZ�-��*�[,��В>S���E1>ʲ(��nPGQ����Z�im����e܃vFWӷ#�A��L�B��yel���=kKC1��k�,��B�y,���:�ϥuP�Fs�֕��X� ��e�1���+V�l�^�ڐΚŖ9�bCp�iڝ�W�u-��� ����y�N� �tP/� Q ����ֲ��e��ץ@�*e���M �� �Xn$�K A
About - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities ENGINEERED GENE THERAPY APPROACH Capsida Biotherapeutics is developing next generation, targeted genetic medicines for rare and more common neurological and ocular diseases across all ages. Naturally occurring AAV capsids have limited the potential application of gene therapies fo
Capsida confirms closure of SYNRGY gene therapy trial BioXconomy is part of the Informa Connect Division of Informa PLC Informa PLC | ABOUT US | INVESTOR RELATIONS | TALENT This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726. About Events Advertise Stay Updated Stay Updated Partnering Related Topics Licensing M&A Growth Strategy Recent in Partnering See All Partnering ‘I'd like it to be our secret’: Why pharma execs
Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities February 21, 2024 Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference THOUSAND OAKS, Calif., February 21, 2024 — Capsida Biotherapeutics (“Capsida”) today announced
Frank Verwiel, M.D. - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities Frank Verwiel, M.D. Frank Verwiel M.D. was President, CEO and Board member of Aptalis Pharma (previously known as Axcan Pharma (NASDAQ: AXCA)) from 2005 until 2014. Frank led the LBO that resulted in Aptalis to be acquired in 2008 by TPG Capital for $1.3 billion. In
Capsida to Present Preclinical Data of New Next-Generation, High-Performing Ocular Capsids at ASGCT Annual Meeting - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities May 12, 2026 Capsida to Present Preclinical Data of New Next-Generation, High-Performing Ocular Capsids at ASGCT Annual Meeting Provides corporate update including appointm
Careers - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities BE A PART OF OUR DNA CULTURE AND BENEFITS Seize the opportunity to be at the forefront of gene therapy. Capsida is a vibrant company based in the heart of the Greater Los Angeles biotech hub. We’re looking for passionate, dedicated colleagues to join us. OUR VALUES In It Togethe
Capsida Biotherapeutics gets FDA clearance for CAP-002 gene therapy | Peter Anastasiou posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s … re excited to share that the FDA has cleared the Investigational New Drug (IND) application for CAP-002 to enter clinical trials for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). This is the first program entering a human clinical trial utilizing an intravenously administered, blood-brain barrier-crossing engineered capsid that also is detargeted from off-target tissues, like liver and dorsal root ganglia. STXBP1-DEE is estimated to affec … Different - First FDA-approved incision-free therapy for keratoconus. - Topical application avoids the need to remove the corneal epithelium, reducing pain and recovery time. - Represents a new standard of care for patients with this sight-threatening disease. - Expected to be commercially available in Q1 2026. 📊 Clinical Significance - Epioxa™ demonstrated statistically significant improvements in halting disease progression compared to placebo. - Patients experienced bette
%PDF-1.7 %���� 1 0 obj >/Metadata 3059 0 R/ViewerPreferences 3060 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��XKo7� ��q7��� �$ 4�[���A�eY�,���4��� �iIN+'�e�3��|�ג;~��.�'ӭ8��J�9 ��EQ(�� J_g �� �>��`����p�ļY\xU�[}�l8�i8o�u|Ć�V�C6�'��l��{1>�~ f2DRJ'U���p@���(+}�F=��}p�`�R㕰��& �� ϟ�?�z�Z/^��� �)ꏧK/�:�X�-�hO�WrI�/�&���8Y�E6[�~�� ��O�0�DVt�j��� ��,cr*�9M�B�١}Nr���lB��܄�>7.[��F !��:Bm�:�-���O�(�����B!���x� �
Careers - Capsida Biotherapeutics About Overview Leadership Team Board of Directors Investors History Contact Innovation Capsida Approach CNS Ophthalmology Capsid Engineering and Preclinical Manufacturing Operations News Press Releases Community Updates Publications Careers Culture & Benefits Current Opportunities BE A PART OF OUR DNA CULTURE AND BENEFITS Seize the opportunity to be at the forefront of gene therapy. Capsida is a vibrant company based in the heart of the Greater Los Angeles biotech hub. We’re looking for passionate, dedicated colleagues to join us. OUR VALUES In It Togethe